Skip to main content

Table 1 Patients’ demographic and clinical characteristics

From: Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study

Variable

Patients: n (%)a

Gender

 Male

274 (49)

 Female

281 (51)

Age

  ≤ 30

120 (21.6)

 31–40

94 (16.9)

 41–50

122 (22)

  > 50

219 (39.5)

Overall prescribed drugsb

  ≤ 5

111 (20)

 6–7

114 (20.5)

 8–9

131 (23.6)

  ≥ 10

199 (35.9)

Diagnoses

 Breast cancer

86 (15.5)

 Non hodgkin lymphoma

84 (15.1)

 Gastrointestinal cancer

71 (12.8)

 Gynecologic cancer

33 (5.9)

 Acute lymphoblastic leukemia

29 (5.2)

 Genitourinary cancer

23 (4.1)

 Hodgkin lymphoma

17 (3.1)

 Chronic lymphocytic leukemia

15 (2.7)

 Musculoskeletal cancer

14 (2.5)

 Acute mylogenous leukemia

11 (2)

 Ovarian cancer

11 (2)

 Colorectal carcinoma

11 (2)

 Lung cancer

10 (1.8)

 Head and neck cancer

8 (1.4)

Comorbidities

 Diabetes mellitus

27 (4.9)

 Hypertension

23 (4.1)

 Hepatitis B

3 (0.5)

 Hepatitis C

3 (0.5)

  1. aPercentage calculated in total number of patients i.e., 555
  2. bOverall prescribed medications mean QT prolonging medications as well as other medications